Selected studies reporting the incidence of hypertension and atrial fibrillation in patients on ibrutinib monotherapy
| Cohorts* . | N† . | Median follow-up (mo) . | Hypertension, any (% or person-years) . | Hypertension, grade 3-4 (%) . | Atrial fibrillation, any (%) . | Comment . |
|---|---|---|---|---|---|---|
| Dickerson et al and the Framingham cohort | ||||||
| Dickerson et al (entire cohort) | 562 | 30 | 78% | 38 | 13 | BP cutoff for hypertension: ≥130/80 mmHg |
| Dickerson et al (subset)‡ | 157 | 30 | 442/1000 person-years§ | NR | NR | BP cutoff for hypertension: ≥140/90 mmHg |
| Framingham (subset)‡ | NR | NR | 34/1000 person-years§ | NR | NR | BP cutoff for hypertension: ≥140/90 mmHg |
| Other studies | ||||||
| RESONATE7 | 195 | 44 | NR | 8 | 11 | |
| RESONATE-28 | 136 | 29 | NR | 5 | 10 | |
| RESONATE-179 | 144 | 28 | 30% | 13 | 7 | |
| Alliance5 | 182 | 32 | NR | 29 | 9 | Grade 3-4 hypertension occurred more frequently in the ibrutinib arms (29%-34%) than in the chemotherapy arm (15%). |
| PCYC-1102/110310 | 132 | 62 | NR | 27 | 11 (grade 3-4) |
| Cohorts* . | N† . | Median follow-up (mo) . | Hypertension, any (% or person-years) . | Hypertension, grade 3-4 (%) . | Atrial fibrillation, any (%) . | Comment . |
|---|---|---|---|---|---|---|
| Dickerson et al and the Framingham cohort | ||||||
| Dickerson et al (entire cohort) | 562 | 30 | 78% | 38 | 13 | BP cutoff for hypertension: ≥130/80 mmHg |
| Dickerson et al (subset)‡ | 157 | 30 | 442/1000 person-years§ | NR | NR | BP cutoff for hypertension: ≥140/90 mmHg |
| Framingham (subset)‡ | NR | NR | 34/1000 person-years§ | NR | NR | BP cutoff for hypertension: ≥140/90 mmHg |
| Other studies | ||||||
| RESONATE7 | 195 | 44 | NR | 8 | 11 | |
| RESONATE-28 | 136 | 29 | NR | 5 | 10 | |
| RESONATE-179 | 144 | 28 | 30% | 13 | 7 | |
| Alliance5 | 182 | 32 | NR | 29 | 9 | Grade 3-4 hypertension occurred more frequently in the ibrutinib arms (29%-34%) than in the chemotherapy arm (15%). |
| PCYC-1102/110310 | 132 | 62 | NR | 27 | 11 (grade 3-4) |
NR, not reported
Publications cited in this table are the reports with the longest follow-up to date per cohort.
Number of patients treated with ibrutinib monotherapy (excluding patients on comparison arms in randomized studies).
A selected subset of each cohort who were age 20 to 69 years and had no diabetes.
Cumulative incidence at 1 year.